Document 6561509

Transcription

Document 6561509
NEWS
th
MONTH
2014
1300th
October
2014
We continue to see risk to the downside in markets this week, given the growing fears regarding economic slowdown and
disinflation in the Eurozone. Markets were mostly lower last week and while dovish comments from the Fed gave a slight
reprieve Wednesday evening, weaker German export data and global GDP downgrades from the IMF saw markets
reverse gains in the second half of the week. Q3 earnings season gathers pace this week and we see this driving market
momentum. In our view, there is significant potential for earnings to disappoint this quarter, given diminishing global
growth. Economic releases should also influence momentum in the days ahead, with UK CPI Tuesday; Chinese and
German CPI, Empire Manufacturing and US Beige Book on Wednesday; US Industrial Production and Philly Fed on
Thursday; and University of Michigan Consumer Confidence to end the week. Given current market volatility, our
preference remains for cash and selective defensive names.
This week’s market events
Equities Commentary
M
Carrefour – Removal from core portfolio on Sector Technicals
We are removing Carrefour (BUY, TP: €32.50) from the core portfolio on the basis of our
Technical Analysts outlook for the Euro Stoxx 600 Retail sector. We remain Technical bears
on the sector since its breakout below the longer term trend line support. Momentum
indicators for the sector also remain bearish in the medium term. Fundamentally we retain a
BUY rating on Carrefour, however shorter term we believe the shares could come under
further pressure due to the general market and sector weakness. We keep the proceeds of
the sale in cash, bringing our total cash allotment in the core portfolio to 11.5% - the highest
level this year.
CORPORATE
n/a
T
CORPORATE
Intel – Q3
JP Morgan – Q3
Citigroup – Q3
JP Morgan – Remain positive ahead of results
Ahead of results this week, we continue to like JP Morgan in the US Banking sector.
Historically, JPM has beaten expectations in Q3 every year for the last 5 years. QoQ, the
bank has surpassed estimates in 7 of the last 8 quarters. Though investment banking fees
in the industry have soared this year, JPM can also boast a strong consumer and
commercial lending business. Bloomberg consensus expectations are for EPS of $1.384 for
the third quarter and a DPS of $0.40. JPMorgan shares trade on 1.4x Tangible Book value,
which we believe is an unwarranted discount to peers on 1.6x.
Equities
Portfolio Management
Research
UK – CPI YoY
GE – ZEW Survey
Exp.
Burberry- H115
W
CORPORATE
ECONOMICS
eBay – Q3
CH – PPI YoY
Danone – Q3
CH – CPI YoY
GE – CPI YoY
Rio Tinto – Q3
Bank of America – US – Empire Manuf.
Q3
US – Fed Beige
Book
Netflix – Q3
T
CORPORATE
ECONOMICS
Carrefour – Q3
EZ – CPI YoY
Google – Q3
US – Indus. Prod.
MoM
US – Philadelphia
Fed Business
Outlook
Nestle –Q3
Man Group – Q3
Mondi – Q3
Diageo – Q1
Earnings Outlook – Downgrades continue into Q4
As highlighted above, earnings season is kicking off in earnest this week, to a backdrop of a
weaker Eurozone, reduced global growth and on-going geo-political tensions. Earnings
forecasts have reduced steadily over the course of the year. Market expectations for full
year growth in the S&P are now just 7.3%, broadly in line with our expectations at the start
of the year. S&P earnings for Q3 are now expected to be ~4.5%, down from 8.9% in June,
while European expectations are for a 5.4% annual increase, down from 13% at the start of
2014. The impact of Russian sanctions during the quarter will also become clear, with a
number of companies already warning of a negative impact to bottom line. While markets
remain volatile, sector selection is an important consideration. We see the greatest
likelihood of earnings outperformance in Q3 in the Pharmaceutical, Telcoms and Insurance
sectors, while we see the greatest downside risk in Industrials, Energy and Consumer
Discretionary.
ECONOMICS
SAB Miller- Q2
Core Portfolio – 11.5% cash position reflective of our near term Bearish view
We forecast in our Q3 Outlook that “market volatility (will) increase in the latter stages
of the quarter and into the start of Q4, as increasingly divergent Central Bank policy
creates an uncertain interest rate backdrop”. We believe equity markets have not
accurately priced in the benign earnings environment, weaker global growth, or the level of
geopolitical risk. We reiterated that view in our Q4 Quarterly Outlook released last week
(which can be found here). In light of this we reduced our equity exposure over recent
months by removing Siemens (N/C) and now Carrefour, while also realising some profits in
Intel (N/C) and Apple (BUY, TP $123). Our cash position now stands at 11.5% of the core
portfolio. We have positioned the portfolio to take advantage of attractive valuations where
they exist, and in defensive names in our preferred sectors.
ECONOMICS
CH - Trade Balance
American Express –
Q3
Goldman Sachs –
Q3
F
CORPORATE
Travis Perkins –
Q3
GE – Q3
ECONOMICS
US – Univ. Michigan
Confidence
Upcoming Events
20/10/14
20/10/14
Apple – Q3
SAP – Q3
20/10/14
IBM – Q3
21/10/14
21/10/14
21/10/14
21/10/14
21/10/14
Verizon – Q3
GKN – Q3
William Hill – Q3
Coca Cola – Q3
ARM – Q3
22/10/14
GSK – Q3
Bonds
Regulatory Information
This material is approved for distribution in Ireland by Cantor Fitzgerald Ireland Ltd. Cantor Fitzgerald Ireland Ltd (“CFIL”) is regulated by the Central
Bank of Ireland. Cantor Fitzgerald Ireland Ltd is a member firm of the Irish Stock Exchange and the London Stock Exchange.
Where CFIL wishes to make this and other Cantor Fitzgerald research available to Retail clients, such information is provided without liability and in
accordance with our terms and conditions that are available on the CFIL website.
No report is intended to and does not constitute a personal recommendations or investment advice nor does it provide the sole basis for any
evaluation of the securities that may be the subject matter of the report. Specifically, the information contained in this report should not be taken as
an offer or solicitation of investment advice, or to encourage the purchased or sale of any particular security. Not all recommendations are
necessarily suitable for all investors and CFIL recommend that specific advice should always be sought prior to investment, based on the particular
circumstances of the investor either from your CFIL investment adviser or another investment adviser.
CFIL takes all responsibility to ensure that reasonable efforts are made to present accurate information but CFIL gives no warranty or guarantee as
to, and do not accept responsibility for, the correctness, completeness, timeliness or accuracy of the information provided or its transmission. This is
entirely at the risk of the recipient of the report. Nor shall CFIL, its subsidiaries, affiliates or parent company or any of their employees, directors or
agents, be liable to for any losses, damages, costs, claims, demands or expenses of any kind whatsoever, whether direct or indirect, suffered or
incurred in consequence of any use of, or reliance upon, the information. Any person acting on the information contained in this report does so
entirely at his or her own risk
All estimates, views and opinions included in this research note constitute CANTOR IRELAND’s judgment as of the date of the note but may be
subject to change without notice. Changes to assumptions may have a material impact on any recommendations made herein.
Unless specifically indicated to the contrary this research note has not been disclosed to the covered issuer(s) in advance of publication.
Past performance is not a reliable guide to future performance. The value of your investment may go down as well as up. Investments denominated
in foreign currencies are subject to fluctuations in exchange rates, which may have an adverse affect on the value of the investments, sale proceeds,
and on dividend or interest income. The income you get from your investment may go down as well as up. Figures quoted are estimates only; they
are not a reliable guide to the future performance of this investment.
Conflicts of Interest & Share Ownership Policy
It is noted that research analysts' compensation is impacted upon by overall firm profitability and accordingly may be affected to some extent by
revenues arising other CANTOR IRELAND business units including Fund Management and Stock broking. Revenues in these business units may
derive in part from the recommendations or views in this report. Notwithstanding, CANTOR IRELAND is satisfied that the objectivity of views and
recommendations contained in this note has not been compromised. Nonetheless CANTOR IRELAND is satisfied that the impartiality of research,
views and recommendations remains assured.
Our conflicts of interest management policy is available at the following link;
http://www.cantorfitzgerald.ie/regulation_mifld.shtml
Analyst Certification
Each research analyst responsible for the content of this research note, in whole or in part, certifies that: (1) all of the views expressed accurately
reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly,
related to the specific recommendations or views expressed by that research analyst in the research note.
US distribution
This research note is being distributed by (CF Ireland / CF Europe / CF US / CF Canada / CF Hong Kong) in the United States and is intended for
distribution in the United States solely to “major U.S. institutional investors” (as such term is defined in Rule15a-6 of the U.S. Securities Exchange
Act of 1934 and applicable interpretations relating thereto) and is not intended for the use of any person or entity that is not a major institutional
investor. This material is intended solely for institutional investors and investors who Cantor reasonably believes are institutional investors. It is
prohibited for distribution to non-institutional clients including retail clients, private clients and individual investors. Major Institutional Investors
receiving this research note should effect transactions in securities discussed in this research note through Cantor Fitzgerald & Co. This research
note has been prepared in whole or in part by research analysts employed by non-US affiliates of Cantor Fitzgerald & Co that are not registered as
broker-dealers in the United States. These non-US research analysts are not registered as associated persons of Cantor Fitzgerald & Co. and are
not licensed or qualified as research analysts with FINRA or any other US regulatory authority and, accordingly, may not be subject (among other
things) to FINRA’s restrictions regarding communications by a research analyst with a subject company, public appearances by research analysts,
and trading securities held by a research analyst account.
UK distribution
This research note is approved for distribution in the United Kingdom by Cantor Fitzgerald Europe (“CFE”). CFE is authorised and regulated by the
Financial Conduct Authority (“FCA”). While we believe this information and the materials upon which this information was based is accurate, except
for any obligations under the rules of the FCA, we do not guarantee its accuracy. This material is only intended for use by eligible counterparties or
professional clients who fall within articles 19 or 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 and not the
general investing public. None of the investments or investment services mentioned or described herein are available to other persons in the U.K
and in particular are not available to "retail clients” as defined by the rules of the FCA.
Other important disclosures
Prices quoted in this research note, unless otherwise indicated, are as of close on the previous trading day.
The distribution of this research note in other jurisdictions may be restricted by law and persons into whose possession this specialist sales market
commentary publication comes should inform themselves about and observe any such restrictions. By accepting this research note you agree to be
bound by the foregoing instructions.
Sources: CANTOR IRELAND Research, Bloomberg
Dublin: 75 St. Stephen’s Green, Dublin 2, Ireland. Tel : +353 1 633 3800. Fax : +353 1 633 3856/+353 1 633 3857
CORK: Dolmen House, 45 South Mall, Cork. Tel: +353 21 422 2122.
LIMERICK: Theatre Court, Lower Mallow Street, Limerick. Tel: +353 61 436500.
Email : ireland@cantor.com web : www.cantorfitzgerald.ie
Equities
Portfolio Management
Research
Bonds